about
Linking power Doppler ultrasound to the presence of th17 cells in the rheumatoid arthritis jointPatient involvement in rheumatology outpatient service design and delivery: a case study.Interleukin-17+CD8+ T cells are enriched in the joints of patients with psoriatic arthritis and correlate with disease activity and joint damage progressionRheumatoid arthritis patients with fibromyalgic clinical features have significantly less synovitis as defined by power Doppler ultrasoundPredicting responses in patients with rheumatoid arthritis to disease-modifying agents using baseline clinical data.Current perspectives on tocilizumab for the treatment of rheumatoid arthritis: a reviewIn vivo activated monocytes from the site of inflammation in humans specifically promote Th17 responsesTNF-α blockade induces IL-10 expression in human CD4+ T cells.Interaction with activated monocytes enhances cytokine expression and suppressive activity of human CD4+CD45ro+CD25+CD127(low) regulatory T cells.Co-morbidities in established rheumatoid arthritis.Goal-directed therapy for RA in routine practice is associated with improved function in patients with disease duration up to 15 years.FAS/FAS-L dependent killing of activated human monocytes and macrophages by CD4+CD25- responder T cells, but not CD4+CD25+ regulatory T cells.An examination of work instability, functional impairment, and disease activity in employed patients with rheumatoid arthritis.Abatacept in the treatment of adult dermatomyositis and polymyositis: a randomised, phase IIb treatment delayed-start trial.Rheumatoid arthritis: clinical utility of the RAID (RA impact of disease) score.BSR and BHPR guideline for the prescription and monitoring of non-biologic disease-modifying anti-rheumatic drugs.Enhanced and persistent levels of interleukin (IL)-17⁺ CD4⁺ T cells and serum IL-17 in patients with early inflammatory arthritis.BSR and BHPR guideline for the prescription and monitoring of non-biologic disease-modifying anti-rheumatic drugs.TNF-inhibitor drugs regulate human pathogenic Th17 cells through induction of IL-10Real world long-term impact of intensive treatment on disease activity, disability and health-related quality of life in rheumatoid arthritisA synovial pathergy reaction leading to a pseudo-septic arthritis and a diagnosis of Behçet's diseaseDrug therapy of inflammatory arthritis
P50
Q33687116-95835D72-F602-47FD-A773-9DB7915F6C5DQ33693177-769546CE-357A-4845-830A-67D57E3C9A0CQ34154244-13280836-5918-46B8-92F4-20944C5AC34DQ36141747-0985889E-932F-40A0-90DD-0779EE8D2656Q36374664-9832387B-7003-4E25-AB9F-756A2B314887Q36996859-93106FB4-33FC-4DDC-8B7E-82A97569B1DEQ37159003-09B528C3-EB87-4D74-9B6E-F4FF561F3EB5Q37570592-BCB974BE-4AD5-4946-B71A-10ED30CB2900Q37627037-876998A5-692F-4F4E-94F6-0647B6F7ADECQ37964309-C051B852-ECEC-4214-BF4B-8A43B6E8FC4CQ42578641-88603590-6037-4E59-A0B2-9389D6D74101Q44215595-1FFCFF21-CDF6-43CD-95A8-593A656C6497Q45763104-F8171C0E-7D9D-4FBC-A40E-4B87AD05EB1BQ47674978-9E74F2C1-F583-415D-A290-A3723373452DQ48292538-F982E25A-858E-4029-9749-3A4ED581D414Q50065362-26FD202E-FE05-4E6D-AD1B-72F410F3DE19Q50866589-8F299A2C-725B-44D8-B7BC-ED957B967947Q53736769-8403AADA-ACE7-4AE2-A4F9-24C3663F4BACQ57720692-8DAAC4B8-9F45-4D07-B366-E8801562BD13Q64103938-81F5E3EA-D0EE-4C12-9775-09373AF578C5Q81398636-B9265C8D-CFCB-4D24-8A08-89A3B076D267Q84892267-01A0E1DC-1F3C-4B21-A72C-90FB9FFE0B09
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Nicola J Gullick
@ast
Nicola J Gullick
@en
Nicola J Gullick
@es
Nicola J Gullick
@nl
type
label
Nicola J Gullick
@ast
Nicola J Gullick
@en
Nicola J Gullick
@es
Nicola J Gullick
@nl
prefLabel
Nicola J Gullick
@ast
Nicola J Gullick
@en
Nicola J Gullick
@es
Nicola J Gullick
@nl
P108
P106
P108
P1153
16031126500
P21
P31
P496
0000-0001-8970-4116